Stem cell enhancing therapeutics
a stem cell and therapeutic technology, applied in the direction of drug compositions, peptides, extracellular fluid disorders, etc., can solve the problems of cytotoxic drugs killing cancer cells but also killing healthy cells, affecting the effect of chemotherapy, and affecting the survival rate of patients
Inactive Publication Date: 2017-05-04
MINERVA BIOTECH
View PDF1 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The patent text is discussing a method for selecting antibodies that can stimulate the growth of stem cells while inhibiting the growth of cancer cells. The antibodies are designed to have two arms that can bind to the stem cells, allowing them to grow. However, when the antibodies have just one arm, they prevent the stem cells from growing. This technique may help to develop new treatments for stem cell-related diseases.
Problems solved by technology
A problem encountered by oncologists is that they must balance the benefit of chemotherapy against the risk of killing the patient during the course of killing their cancers.
One of the life-threatening side effects of chemotherapy is that cytotoxic drugs kill cancer cells but also kill healthy cells and in particular kill the patients' stem cells.
Chemo and radiation can destroy the stem cells which eventually become blood cells and thus put the patient's life at risk, which makes the physician reduce the cancer killing treatments.
The problem with designing agents to counter these deleterious effects of cancer treatment is that blood cells are terminally differentiated cells—meaning that they cannot divide to replicate themselves.
This means that it is not possible to collect some red or white blood cells from a patient and expand them in vitro then inject them back into the patient.
These drugs do not stimulate the growth of stem cells in the bone marrow but rather skew the development of the patient's stem cells such that more become blood cells of the erythroid lineage.
However, a drawback of G-CSF and GM-CSF is that they inhibit bone formation.
It follows that there may be unwanted and dangerous side effects stemming from the inhibition of other types of cells that are produced in the bone marrow.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example 1
Development of Monoclonal Antibodies, 2D6C8 and 2D6C3 (Also Referred to Here as C3 and C8) that Facilitate Human Stem Cell Attachment to Surfaces
[0143]MUC1* monoclonal antibodies were identified that preferentially bound to the portion of the MUC1* extra cellular domain that is more distal from the cell surface and these monoclonals were shown to better facilitate the attachment of human ES and iPS cells to surfaces. Mice were immunized with a peptide that is defined by the PSMGFR sequence. Supernatants of hybridoma clones were tested by ELISA for their ability to bind to the PSMGFR peptide and by FACS to determine which bound to live, MUC1* positive cells. Hybridomas were further selected if they preferentially bound to the PSMGFR peptide lacking 10 C-terminal amino acids, but did not bind if the peptide lacked the 10 N-terminal peptides. In addition, hybridomas were screened for their ability to facilitate stem cell attachment to a surface such as a plastic cell culture plate. Of ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| concentrations | aaaaa | aaaaa |
| volume | aaaaa | aaaaa |
| volumes | aaaaa | aaaaa |
Login to View More
Abstract
Description
BACKGROUND[0001]A problem encountered by oncologists is that they must balance the benefit of chemotherapy against the risk of killing the patient during the course of killing their cancers. One of the life-threatening side effects of chemotherapy is that cytotoxic drugs kill cancer cells but also kill healthy cells and in particular kill the patients' stem cells. Stem cells in the bone marrow are constantly regenerating to supply the body with red blood cells, which carry oxygen, white blood cells, which fight infection and platelets which cause the blood to clot. Chemo and radiation can destroy the stem cells which eventually become blood cells and thus put the patient's life at risk, which makes the physician reduce the cancer killing treatments. The problem with designing agents to counter these deleterious effects of cancer treatment is that blood cells are terminally differentiated cells—meaning that they cannot divide to replicate themselves. They developed from hematopoietic...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28
CPCC07K16/28C07K2317/34C07K2317/75C07K2317/35C07K2317/73C07K16/3092A61P13/08A61P13/12A61P35/00A61P43/00A61P7/00C07K2317/30C07K2317/33C07K2317/74
Inventor BAMDAD, CYNTHIA
Owner MINERVA BIOTECH